MBX
MBX Biosciences, Inc. Common Stock NASDAQ$29.60
Mkt Cap $994.4M
52w Low $9.43
56.9% of range
52w High $44.89
50d MA $31.04
200d MA $25.31
P/E (TTM)
-12.5x
EV/EBITDA
-11.0x
P/B
2.9x
Debt/Equity
0.0x
ROE
-23.6%
P/FCF
-14.1x
RSI (14)
—
ATR (14)
—
Beta
1.25
50d MA
$31.04
200d MA
$25.31
Avg Volume
550.8K
About
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chroni…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.64 | -0.49 | +23.4% | 27.95 | -0.5% | +0.2% | +6.6% | +6.4% | +2.7% | +1.7% | — |
| Nov 6, 2025 | AMC | -0.73 | -0.63 | +13.7% | 24.74 | -11.4% | +3.4% | -1.0% | +0.7% | -0.6% | -2.7% | — |
| Aug 7, 2025 | AMC | -0.77 | -0.58 | +24.7% | 11.13 | +0.5% | +9.3% | +1.2% | +12.6% | +16.4% | +18.7% | — |
| May 12, 2025 | AMC | -0.81 | -0.71 | +12.3% | 11.14 | +0.6% | -7.8% | -8.7% | -4.4% | +0.2% | +9.1% | — |
| Mar 17, 2025 | AMC | -0.59 | -0.47 | +20.3% | 8.85 | -2.8% | -4.9% | -5.1% | -9.9% | -10.8% | -8.1% | — |
| Nov 7, 2024 | AMC | -2.72 | -2.78 | -2.2% | 23.22 | +0.4% | -1.3% | +1.2% | -2.2% | -10.2% | -16.1% | — |
| Aug 23, 2024 | AMC | — | -11.47 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -0.26 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.32 | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 16 | Guggenheim | Maintains | Buy → Buy | — | $40.91 | $41.23 | +0.8% | -0.9% | +5.5% | +0.4% | +3.6% | -7.5% |
| Dec 19 | Stifel | Maintains | Buy → Buy | — | $28.67 | $29.33 | +2.3% | +6.1% | +21.4% | +12.3% | +12.0% | +7.8% |
| Nov 10 | Guggenheim | Maintains | Buy → Buy | — | $25.57 | $26.20 | +2.5% | -4.2% | -2.6% | -3.8% | -5.9% | -3.1% |
| Sep 24 | Mizuho | Maintains | Outperform → Outperform | — | $18.96 | $19.74 | +4.1% | +6.0% | -8.6% | -7.6% | -5.4% | -7.7% |
| Sep 23 | Guggenheim | Maintains | Buy → Buy | — | $20.00 | $19.99 | -0.1% | -5.2% | +0.5% | -13.3% | -12.4% | -10.3% |
| Sep 23 | Oppenheimer | Maintains | Outperform → Outperform | — | $20.00 | $19.99 | -0.1% | -5.2% | +0.5% | -13.3% | -12.4% | -10.3% |
| Apr 10 | Guggenheim | Maintains | Buy → Buy | — | $6.40 | $6.56 | +2.5% | -2.0% | +15.8% | +16.1% | +15.3% | +17.3% |
Recent Filings
8-K
Unknown — 8-K Filing
MBX's 2025 clinical validation of its precision peptide platform de-risks its pipeline and positions the company for potential regulatory approvals, making it attractive for investors betting on novel endocrine-metabolic therapies.
Mar 12
8-K · 8.01
!! High
MBX Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
MBX Biosciences completed a successful FDA End-of-Phase 2 meeting for canvuparatide, positioning the once-weekly treatment to advance into Phase 3 trials for chronic hypoparathyroidism in Q3 2026.
Mar 9
8-K · 5.02
!!! Very High
MBX Biosciences, Inc. -- 8-K 5.02: Executive Change
MBX Biosciences replaced CFO Richard Bartram with interim CFO John Smither, effective March 16, 2026, signaling potential leadership transition during a critical period for the company.
Feb 27
8-K · 8.01
!! High
MBX Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
MBX Biosciences sold shares under its ATM program with Jefferies on February 4, 2026, providing capital funding through its previously established November 2025 agreement.
Feb 5
Data updated apr 25, 2026 8:53pm
· Source: massive.com